期刊
ANTIOXIDANTS
卷 10, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/antiox10111669
关键词
chronic kidney disease; antioxidants; meta-analysis; bardoxolone methyl; pentoxifylline; nephroprotection
资金
- Instituto de Salud Carlos III [PI18/00996, PI20/01351, Retic RD016/0009/0025]
- FEDER funds
Antioxidant therapy appears to reduce the progression of chronic kidney disease, with pentoxifylline and bardoxolone methyl showing the most robust protection. However, individual variability and potential off-target effects introduce uncertainty regarding the role of oxidative stress in CKD progression and the effectiveness of antioxidant therapy. Personalized antioxidant therapy based on individual factors is necessary for optimal treatment outcomes.
Chronic kidney disease (CKD) is a progressive impairment of renal function for more than three months that affects 15% of the adult population. Because oxidative stress is involved in its pathogenesis, antioxidants are under study for the prophylaxis of CKD progression. The objective of this work was to meta-analyze the efficacy of antioxidant therapy in CKD patients and to identify the most effective candidate antioxidants. Our meta-analysis showed that, despite being quite heterogeneous, overall antioxidant therapy apparently reduced CKD progression. Pentoxifylline and bardoxolone methyl demonstrated a robust and statistically significant protection, while other products showed a favorable but non-significant tendency, due to a high interindividual variability. Off-target (i.e., antioxidant-independent) effects, such as body weight reduction and heart failure-associated blood dilution, might totally or partially explain the protection provided by effective antioxidants. This potential pleiotropy introduces uncertainty on the role of oxidative stress in CKD progression and on antioxidant therapy in its prevention, which needs to be further investigated. Independently, identification of factors determining the nephroprotective effect of each candidate on each patient is thus necessary for a prospectively personalized antioxidant therapy. Finally, pentoxifylline should be further explored for the prophylaxis of CKD progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据